- Home
- APXT vs CLLS Comparison
APXT vs CLLS Comparison
Compare APXT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APXT | CLLS |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.1M | 476.5M |
| IPO Year | 2025 | 2007 |
Fundamental Metrics
Financial Performance| Metric | APXT | CLLS |
|---|---|---|
| Price | $9.88 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 78.3K | ★ 114.5K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $9.87 | $1.10 |
| 52 Week High | $9.96 | $5.48 |
Technical Indicators
Market Signals| Indicator | APXT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.29 |
| Support Level | N/A | $4.37 |
| Resistance Level | N/A | $4.97 |
| Average True Range (ATR) | 0.00 | 0.25 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 53.78 |
Price Performance
Historical ComparisonAbout APXT Apex Treasury Corporation Class A Ordinary Share
Apex Treasury Corp is a blank check company established for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.